drugset

drugset / Trial / NCT01848756

Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers

NCT01848756 ↗

Phase 1/2 Terminated 15 enrolled Esanex Inc.

NaSingle-groupOpen-labelTreatment

Summary

Hsp90 is a chemical in the body that is involved in the promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90

Timeline

Start: 2013-04
Primary completion: 2015-02
Completion: 2015-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SNX-5422	Small molecule	100 mg/m2	Oral

Indications